AVCO Stock Overview
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.74|
|52 Week High||US$1.65|
|52 Week Low||US$0.67|
|1 Month Change||-18.97%|
|3 Month Change||-26.53%|
|1 Year Change||-40.16%|
|3 Year Change||-82.46%|
|5 Year Change||-85.16%|
|Change since IPO||6.00%|
Recent News & Updates
Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|AVCO||US Healthcare||US Market|
Return vs Industry: AVCO underperformed the US Healthcare industry which returned 12.7% over the past year.
Return vs Market: AVCO underperformed the US Market which returned 4.2% over the past year.
|AVCO Average Weekly Movement||9.8%|
|Healthcare Industry Average Movement||8.0%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: AVCO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AVCO's weekly volatility (10%) has been stable over the past year.
About the Company
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology.
Avalon GloboCare Fundamentals Summary
|AVCO fundamental statistics|
Is AVCO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVCO income statement (TTM)|
|Cost of Revenue||US$1.06m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||-681.22%|
How did AVCO perform over the long term?See historical performance and comparison
Is Avalon GloboCare undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVCO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVCO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVCO is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: AVCO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVCO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVCO is overvalued based on its PB Ratio (35.4x) compared to the US Healthcare industry average (2.5x).
How is Avalon GloboCare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avalon GloboCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Avalon GloboCare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVCO is currently unprofitable.
Growing Profit Margin: AVCO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVCO is unprofitable, and losses have increased over the past 5 years at a rate of 35.3% per year.
Accelerating Growth: Unable to compare AVCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVCO is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).
Return on Equity
High ROE: AVCO has a negative Return on Equity (-531.74%), as it is currently unprofitable.
How is Avalon GloboCare's financial position?
Financial Position Analysis
Short Term Liabilities: AVCO's short term assets ($1.3M) do not cover its short term liabilities ($4.5M).
Long Term Liabilities: AVCO's short term assets ($1.3M) do not cover its long term liabilities ($4.0M).
Debt to Equity History and Analysis
Debt Level: AVCO's net debt to equity ratio (206.1%) is considered high.
Reducing Debt: AVCO's debt to equity ratio has increased from 0.8% to 234.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVCO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AVCO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34% each year
What is Avalon GloboCare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVCO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVCO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVCO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVCO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Jin (53 yo)
Dr. David K. Jin, M.D., Ph D., serves as the Chief Executive Officer and President of Avalon Globocare Corp. Dr. Jin is a Senior Translational Scientist at the Howard Hughes Medical Institute and Ansary St...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD1.00M) is above average for companies of similar size in the US market ($USD584.85K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Board: AVCO's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.
Avalon GloboCare Corp.'s employee growth, exchange listings and data sources
- Name: Avalon GloboCare Corp.
- Ticker: AVCO
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$65.593m
- Shares outstanding: 88.40m
- Website: https://www.avalon-globocare.com
Number of Employees
- Avalon GloboCare Corp.
- 4400 Route 9 South
- Suite 3100
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/22 23:04|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.